About Mellitus
Mellitus is a company based in Boston (United States) founded in 2011. Mellitus has raised $16.1 million across 10 funding rounds. Mellitus offers products and services including Pengeluaran Cambodia, Live Draw Cambodia, Keluaran Kamboja, and Tabel Data Kamboja. Mellitus operates in a competitive market with competitors including Viome Life Sciences, Proteomics International, Tethys BioScience, SmartZyme and Veralight, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.1 M (USD)
in 10 rounds
-
Latest Funding Round
$2.8 M (USD), Series A
May 07, 2019
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mellitus
Mellitus offers a comprehensive portfolio of products and services, including Pengeluaran Cambodia, Live Draw Cambodia, Keluaran Kamboja, and Tabel Data Kamboja.
Provides official Cambodian lottery results for betting analysis.
Offers real-time draws for accurate lottery outcomes.
Delivers daily lottery output for user predictions.
Compiles historical data for lottery trend analysis.
People of Mellitus
Unlock access to complete
Unlock access to complete
Funding Insights of Mellitus
Mellitus has successfully raised a total of $16.1M across 10 strategic funding rounds. The most recent funding activity was a Series A round of $2.8 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Mellitus
Investment portfolio details for Mellitus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mellitus
Detailed financials for Mellitus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mellitus Comparisons
Peer comparison for Mellitus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mellitus
Mellitus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viome Life Sciences, Proteomics International, Tethys BioScience, SmartZyme and Veralight, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of tests to prevent, treat, and cure chronic diseases, and cancer
|
|
| Locked | Locked | Locked |
Medical technology company at the forefront of predictive diagnostics and bio-analytical services
|
|
| Locked | Locked | Locked |
Develops biological markers for medical diagnostic applications.
|
|
| Locked | Locked | Locked |
Proprietary protein engineering technology is developed for diabetes products.
|
|
| Locked | Locked | Locked |
Offers biomarker screening solutions for early diabetes detection.
|
Detailed competitors of Mellitus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mellitus
Complete news archive for Mellitus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mellitus
Mellitus was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Mellitus is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Mellitus is a funded company, having raised a total of $16.1M across 10 funding rounds to date.
Mellitus was founded in 2011 in Boston, United States, within the biotechnology sector. An in vitro diagnostic assay for diabetes is being developed, drawing on technology licensed from Harvard University. The lead candidate measures the Glycated CD59 biomarker and targets screening, diagnosis, and monitoring of Gestational Diabetes Mellitus. Applications as a companion diagnostic for pharmaceutical development are also pursued.
Mellitus's top competitors include Viome Life Sciences, Proteomics International and SmartZyme.
Mellitus offers Pengeluaran Cambodia, Live Draw Cambodia, Keluaran Kamboja, and Tabel Data Kamboja.